IMMIX BIOPHARMA, INC. IMMX 深 沪
等待开盘 10-09 09:30:00 美东时间
2.54
+0.030
+1.20%
华盛通- 最 高2.69
- 今 开2.52
- 成交量 153.40万股
- 最 低 2.3745
- 昨 收 2.51
- 总市值 7323.86万
- 52周最高 3.20
- 市盈率 静 --
- 换手率 5.32%
- 52周最低 1.34
- 委 比 43.74%
- 总股本 2883.41万
- 历史最高 8.68
- 量 比 2.51
- 振 幅 12.57%
- 历史最低 0.68
- 每 手 1
- 风险率 1.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immix Biopharma To Present An Abstract On Its Therapy NXC-201 At The ASH 67th Annual Meeting December 6–9, 2025, In Orlando, Florida
Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a NXC-201 abstract at the upcoming American Society of
10-08 04:10
Immix Biopharma Surpasses 50% Enrollment In NEXICART-2 Trial For CAR-T NXC-201 In Relapsed/Refractory AL Amyloidosis, Advancing Toward BLA Submission
– On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis –Los Angeles, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.
09-19 01:32
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
Dr. Nancy T. Chang, former CEO of Tanox, Inc., joins Immix Biopharma's board and Goose Capital investment. She led XOLAIR® and other successful drugs to market, generating over $5 billion in sales. Immix Biopharma is advancing NXC-201, a CAR-T therapy for AL Amyloidosis, with promising clinical results and designation as RMAT and ODD.
09-11 13:15
Immix Biopharma Completes Private Placement Transaction
The latest announcement is out from Immix Biopharma ( ($IMMX) ). On September 5...
09-09 04:36
Immix Biopharma Gains Strategic Investment From Goose Capital And Dr. Nancy T. Chang; Financial Terms Not Disclosed
Immix Biopharma, Inc. ("Immix", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it has received
09-09 04:08
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
Immix Biopharma, a clinical-stage biopharma company developing cell therapies for AL Amyloidosis and other serious diseases, has received strategic investment from Goose Capital and Dr. Nancy T. Chang, former CEO of Tanox. Dr. Chang’s expertise includes developing FDA-approved drugs like XOLAIR® and EBGLYSS®, generating over $5B in sales. Goose Capital, focusing on breakthrough technologies, supports Immix’s mission to cure incurable diseases. Im...
09-08 20:05
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio") will present and host institutional investor meetings at the Stifel 2025 Healthcare Conference on November 11-13, 2025, in New York, NY. The Company will offer one-on-one meetings for interested investors, who should contact their Stifel representative to request meetings. A replay link will be available on the Immix website. ImmixBio is developing NXC-201, a st...
08-25 13:30
Immix Biopharma Advances NXC-201 Cell Therapy In AL Amyloidosis And Other Serious Diseases; Plans To Out-License OSD Programs
– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) –– Company plans to partner-out Other Serious Disease programs –– On track for first Biologics License Application (BLA) approved cell
08-07 00:32
Immix Biopharma Announces Other Serious Diseases Strategy
Immix Biopharma announced updates on its CAR-T cell therapy NXC-201, which is being developed for relapsed/refractory AL Amyloidosis and has shown promise in treating other serious diseases. The company plans to partner out its Other Serious Disease (OSD) programs while advancing NXC-201 toward a Biologics License Application (BLA) for its lead indication. NXC-201 features a "digital filter" to reduce non-specific activation and has received RMAT...
08-06 16:30
